194 related articles for article (PubMed ID: 33413208)
1. The oncometabolite R-2-hydroxyglutarate dysregulates the differentiation of human mesenchymal stromal cells via inducing DNA hypermethylation.
Liu L; Hu K; Feng J; Wang H; Fu S; Wang B; Wang L; Xu Y; Yu X; Huang H
BMC Cancer; 2021 Jan; 21(1):36. PubMed ID: 33413208
[TBL] [Abstract][Full Text] [Related]
2. The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo.
Suijker J; Baelde HJ; Roelofs H; Cleton-Jansen AM; Bovée JV
Oncotarget; 2015 Jun; 6(17):14832-42. PubMed ID: 26046462
[TBL] [Abstract][Full Text] [Related]
3. The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells.
Chen JY; Lai YS; Tsai HJ; Kuo CC; Yen BL; Yeh SP; Sun HS; Hung WC
Sci Rep; 2016 Aug; 6():32428. PubMed ID: 27577048
[TBL] [Abstract][Full Text] [Related]
4. Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes.
Jin Y; Elalaf H; Watanabe M; Tamaki S; Hineno S; Matsunaga K; Woltjen K; Kobayashi Y; Nagata S; Ikeya M; Kato T; Okamoto T; Matsuda S; Toguchida J
PLoS One; 2015; 10(7):e0131998. PubMed ID: 26161668
[TBL] [Abstract][Full Text] [Related]
5. 2-hydroxyglutarate inhibits MyoD-mediated differentiation by preventing H3K9 demethylation.
Schvartzman JM; Reuter VP; Koche RP; Thompson CB
Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12851-12856. PubMed ID: 31182575
[TBL] [Abstract][Full Text] [Related]
6. IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Lu C; Ward PS; Kapoor GS; Rohle D; Turcan S; Abdel-Wahab O; Edwards CR; Khanin R; Figueroa ME; Melnick A; Wellen KE; O'Rourke DM; Berger SL; Chan TA; Levine RL; Mellinghoff IK; Thompson CB
Nature; 2012 Feb; 483(7390):474-8. PubMed ID: 22343901
[TBL] [Abstract][Full Text] [Related]
7. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
[TBL] [Abstract][Full Text] [Related]
8. Effect of 20(S)-Hydroxycholesterol on Multilineage Differentiation of Mesenchymal Stem Cells Isolated from Compact Bones in Chicken.
Adhikari R; Chen C; Kim WK
Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33213081
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation of microRNA-149 activates SDF-1/CXCR4 to promote osteogenic differentiation of mesenchymal stem cells.
Li G; An J; Han X; Zhang X; Wang W; Wang S
J Cell Physiol; 2019 Dec; 234(12):23485-23494. PubMed ID: 31206187
[TBL] [Abstract][Full Text] [Related]
10. Murine Mesenchymal Stromal Cells Retain Biased Differentiation Plasticity Towards Their Tissue of Origin.
Ng TT; Mak KH; Popp C; Ng RK
Cells; 2020 Mar; 9(3):. PubMed ID: 32204552
[TBL] [Abstract][Full Text] [Related]
11. Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells.
Boland GM; Perkins G; Hall DJ; Tuan RS
J Cell Biochem; 2004 Dec; 93(6):1210-30. PubMed ID: 15486964
[TBL] [Abstract][Full Text] [Related]
12. In vitro effects of RU486 on proliferation and differentiation capabilities of human bone marrow mesenchymal stromal cells.
Yu Y; Wei N; Stanford C; Schmidt T; Hong L
Steroids; 2012 Jan; 77(1-2):132-7. PubMed ID: 22093480
[TBL] [Abstract][Full Text] [Related]
13. (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers.
Gunn K; Myllykoski M; Cao JZ; Ahmed M; Huang B; Rouaisnel B; Diplas BH; Levitt MM; Looper R; Doench JG; Ligon KL; Kornblum HI; McBrayer SK; Yan H; Duy C; Godley LA; Koivunen P; Losman JA
Cancer Discov; 2023 Jun; 13(6):1478-1497. PubMed ID: 36847506
[TBL] [Abstract][Full Text] [Related]
14. Berberine promotes bone marrow-derived mesenchymal stem cells osteogenic differentiation via canonical Wnt/β-catenin signaling pathway.
Tao K; Xiao D; Weng J; Xiong A; Kang B; Zeng H
Toxicol Lett; 2016 Jan; 240(1):68-80. PubMed ID: 26478571
[TBL] [Abstract][Full Text] [Related]
15. The role of BMP-7 in chondrogenic and osteogenic differentiation of human bone marrow multipotent mesenchymal stromal cells in vitro.
Shen B; Wei A; Whittaker S; Williams LA; Tao H; Ma DD; Diwan AD
J Cell Biochem; 2010 Feb; 109(2):406-16. PubMed ID: 19950204
[TBL] [Abstract][Full Text] [Related]
16. Tissue source determines the differentiation potentials of mesenchymal stem cells: a comparative study of human mesenchymal stem cells from bone marrow and adipose tissue.
Xu L; Liu Y; Sun Y; Wang B; Xiong Y; Lin W; Wei Q; Wang H; He W; Wang B; Li G
Stem Cell Res Ther; 2017 Dec; 8(1):275. PubMed ID: 29208029
[TBL] [Abstract][Full Text] [Related]
17. An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors.
Verdura S; Cuyàs E; Lozano-Sánchez J; Bastidas-Velez C; Llorach-Parés L; Fernández-Arroyo S; Hernández-Aguilera A; Joven J; Nonell-Canals A; Bosch-Barrera J; Martin-Castillo B; Vellon L; Sanchez-Martinez M; Segura-Carretero A; Menendez JA
Carcinogenesis; 2019 Mar; 40(1):27-40. PubMed ID: 30428017
[TBL] [Abstract][Full Text] [Related]
18. Amniotic Mesenchymal Stromal Cells Exhibit Preferential Osteogenic and Chondrogenic Differentiation and Enhanced Matrix Production Compared With Adipose Mesenchymal Stromal Cells.
Topoluk N; Hawkins R; Tokish J; Mercuri J
Am J Sports Med; 2017 Sep; 45(11):2637-2646. PubMed ID: 28541092
[TBL] [Abstract][Full Text] [Related]
19. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
Delahousse J; Verlingue L; Broutin S; Legoupil C; Touat M; Doucet L; Ammari S; Lacroix L; Ducreux M; Scoazec JY; Malka D; Paci A; Hollebecque A
Eur J Cancer; 2018 Feb; 90():83-91. PubMed ID: 29274619
[TBL] [Abstract][Full Text] [Related]
20. Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate.
Chaturvedi A; Araujo Cruz MM; Jyotsana N; Sharma A; Goparaju R; Schwarzer A; Görlich K; Schottmann R; Struys EA; Jansen EE; Rohde C; Müller-Tidow C; Geffers R; Göhring G; Ganser A; Thol F; Heuser M
Leukemia; 2016 Aug; 30(8):1708-15. PubMed ID: 27063596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
